Abnormal oxidative metabolism and O2 transport in muscle phosphofructokinase deficiency

S. F. Lewis, S. Vora, R. G. Haller

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Humans who lack availability of carbohydrate fuels may provide important models for the study of physiological control mechanisms. We compared seven patients who had unavailability of muscle glycogen and blood glucose as oxidative fuels due to muscle phosphofructokinase deficiency (PFKD) with five patients who had a selective defect in long-chain fatty acid oxidation due to carnitine palmitoyltransferase deficiency (CPTD) and with six healthy subjects. Peak cycle exercise work rate, peak O2 uptake (V̇O2), and arteriovenous O2 difference were markedly lower (P < 0.001) for PFKD patients (23 ± 6 W, 14 ± 2 ml·min-1·kg-1, and 7.1 ± 0.5 ml/dl, respectively) than for CPTD patients (142 ± 33 W, 31 ± 4 ml·min-1·kg-1, and 15.0 ± 0.8 ml/dl, respectively) or healthy subjects (171 ± 17 W, 36 ± 1 ml·min-1·kg-1, and 16.4 ± 0.7 ml/dl, respectively). Peak cardiac output (Q̇) was similar (P > 0.05) in all three groups, but the slope of increase in Q̇ (l/min) on V̇O2 (l/min) from rest to exercise (ΔQ̇/ΔV̇O2) was more than twofold greater (P < 0.001) for PFKD patients (11.2 ± 1.2) than for CPTD patients (4.6 ± 0.6) and healthy subjects (4.6 ± 0.2). Increasing availability of blood-borne oxidative substrates capable of metabolically bypassing the defect at phosphofructokinase (by fasting plus prolonged moderate exercise to increase plasma free fatty acids or by iv lactate infusion) increased peak work rate, V̇O2, and arteriovenous O2 difference, lacked consistent effect on peak Q̇, and normalized ΔQ̇/ΔV̇O2 in PFKD patients. The results extend our previous observations in patients with a block in muscle glycogen but not blood glucose oxidation due to phosphorylase deficiency and imply that specific unavailability of muscle glycogen as an oxidizable fuel is primarily responsible for abnormal muscle oxidative metabolism and associated exercise intolerance and exaggerated ΔQ̇/ΔV̇O2 in muscle PFKD. The findings also endorse the concept that factors closely linked with muscle oxidative phosphorylation participate in regulating ΔQ̇/ΔV̇O2, likely via activation of metabolically sensitive muscle afferents.

Original languageEnglish (US)
Pages (from-to)391-398
Number of pages8
JournalJournal of Applied Physiology
Volume70
Issue number1
StatePublished - 1991

Fingerprint

Glycogen Storage Disease Type VII
Phosphofructokinases
Muscles
Glycogen
Exercise
Carnitine O-Palmitoyltransferase
Blood Glucose
Healthy Volunteers
Phosphorylases
Oxidative Phosphorylation
Nonesterified Fatty Acids
Lactic Acid
Fasting
Fatty Acids
Carbohydrates

ASJC Scopus subject areas

  • Endocrinology
  • Physiology
  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Abnormal oxidative metabolism and O2 transport in muscle phosphofructokinase deficiency. / Lewis, S. F.; Vora, S.; Haller, R. G.

In: Journal of Applied Physiology, Vol. 70, No. 1, 1991, p. 391-398.

Research output: Contribution to journalArticle

@article{55b75a75cab4471f868978bf91dbfd54,
title = "Abnormal oxidative metabolism and O2 transport in muscle phosphofructokinase deficiency",
abstract = "Humans who lack availability of carbohydrate fuels may provide important models for the study of physiological control mechanisms. We compared seven patients who had unavailability of muscle glycogen and blood glucose as oxidative fuels due to muscle phosphofructokinase deficiency (PFKD) with five patients who had a selective defect in long-chain fatty acid oxidation due to carnitine palmitoyltransferase deficiency (CPTD) and with six healthy subjects. Peak cycle exercise work rate, peak O2 uptake (V̇O2), and arteriovenous O2 difference were markedly lower (P < 0.001) for PFKD patients (23 ± 6 W, 14 ± 2 ml·min-1·kg-1, and 7.1 ± 0.5 ml/dl, respectively) than for CPTD patients (142 ± 33 W, 31 ± 4 ml·min-1·kg-1, and 15.0 ± 0.8 ml/dl, respectively) or healthy subjects (171 ± 17 W, 36 ± 1 ml·min-1·kg-1, and 16.4 ± 0.7 ml/dl, respectively). Peak cardiac output (Q̇) was similar (P > 0.05) in all three groups, but the slope of increase in Q̇ (l/min) on V̇O2 (l/min) from rest to exercise (ΔQ̇/ΔV̇O2) was more than twofold greater (P < 0.001) for PFKD patients (11.2 ± 1.2) than for CPTD patients (4.6 ± 0.6) and healthy subjects (4.6 ± 0.2). Increasing availability of blood-borne oxidative substrates capable of metabolically bypassing the defect at phosphofructokinase (by fasting plus prolonged moderate exercise to increase plasma free fatty acids or by iv lactate infusion) increased peak work rate, V̇O2, and arteriovenous O2 difference, lacked consistent effect on peak Q̇, and normalized ΔQ̇/ΔV̇O2 in PFKD patients. The results extend our previous observations in patients with a block in muscle glycogen but not blood glucose oxidation due to phosphorylase deficiency and imply that specific unavailability of muscle glycogen as an oxidizable fuel is primarily responsible for abnormal muscle oxidative metabolism and associated exercise intolerance and exaggerated ΔQ̇/ΔV̇O2 in muscle PFKD. The findings also endorse the concept that factors closely linked with muscle oxidative phosphorylation participate in regulating ΔQ̇/ΔV̇O2, likely via activation of metabolically sensitive muscle afferents.",
author = "Lewis, {S. F.} and S. Vora and Haller, {R. G.}",
year = "1991",
language = "English (US)",
volume = "70",
pages = "391--398",
journal = "Journal of Applied Physiology",
issn = "0161-7567",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Abnormal oxidative metabolism and O2 transport in muscle phosphofructokinase deficiency

AU - Lewis, S. F.

AU - Vora, S.

AU - Haller, R. G.

PY - 1991

Y1 - 1991

N2 - Humans who lack availability of carbohydrate fuels may provide important models for the study of physiological control mechanisms. We compared seven patients who had unavailability of muscle glycogen and blood glucose as oxidative fuels due to muscle phosphofructokinase deficiency (PFKD) with five patients who had a selective defect in long-chain fatty acid oxidation due to carnitine palmitoyltransferase deficiency (CPTD) and with six healthy subjects. Peak cycle exercise work rate, peak O2 uptake (V̇O2), and arteriovenous O2 difference were markedly lower (P < 0.001) for PFKD patients (23 ± 6 W, 14 ± 2 ml·min-1·kg-1, and 7.1 ± 0.5 ml/dl, respectively) than for CPTD patients (142 ± 33 W, 31 ± 4 ml·min-1·kg-1, and 15.0 ± 0.8 ml/dl, respectively) or healthy subjects (171 ± 17 W, 36 ± 1 ml·min-1·kg-1, and 16.4 ± 0.7 ml/dl, respectively). Peak cardiac output (Q̇) was similar (P > 0.05) in all three groups, but the slope of increase in Q̇ (l/min) on V̇O2 (l/min) from rest to exercise (ΔQ̇/ΔV̇O2) was more than twofold greater (P < 0.001) for PFKD patients (11.2 ± 1.2) than for CPTD patients (4.6 ± 0.6) and healthy subjects (4.6 ± 0.2). Increasing availability of blood-borne oxidative substrates capable of metabolically bypassing the defect at phosphofructokinase (by fasting plus prolonged moderate exercise to increase plasma free fatty acids or by iv lactate infusion) increased peak work rate, V̇O2, and arteriovenous O2 difference, lacked consistent effect on peak Q̇, and normalized ΔQ̇/ΔV̇O2 in PFKD patients. The results extend our previous observations in patients with a block in muscle glycogen but not blood glucose oxidation due to phosphorylase deficiency and imply that specific unavailability of muscle glycogen as an oxidizable fuel is primarily responsible for abnormal muscle oxidative metabolism and associated exercise intolerance and exaggerated ΔQ̇/ΔV̇O2 in muscle PFKD. The findings also endorse the concept that factors closely linked with muscle oxidative phosphorylation participate in regulating ΔQ̇/ΔV̇O2, likely via activation of metabolically sensitive muscle afferents.

AB - Humans who lack availability of carbohydrate fuels may provide important models for the study of physiological control mechanisms. We compared seven patients who had unavailability of muscle glycogen and blood glucose as oxidative fuels due to muscle phosphofructokinase deficiency (PFKD) with five patients who had a selective defect in long-chain fatty acid oxidation due to carnitine palmitoyltransferase deficiency (CPTD) and with six healthy subjects. Peak cycle exercise work rate, peak O2 uptake (V̇O2), and arteriovenous O2 difference were markedly lower (P < 0.001) for PFKD patients (23 ± 6 W, 14 ± 2 ml·min-1·kg-1, and 7.1 ± 0.5 ml/dl, respectively) than for CPTD patients (142 ± 33 W, 31 ± 4 ml·min-1·kg-1, and 15.0 ± 0.8 ml/dl, respectively) or healthy subjects (171 ± 17 W, 36 ± 1 ml·min-1·kg-1, and 16.4 ± 0.7 ml/dl, respectively). Peak cardiac output (Q̇) was similar (P > 0.05) in all three groups, but the slope of increase in Q̇ (l/min) on V̇O2 (l/min) from rest to exercise (ΔQ̇/ΔV̇O2) was more than twofold greater (P < 0.001) for PFKD patients (11.2 ± 1.2) than for CPTD patients (4.6 ± 0.6) and healthy subjects (4.6 ± 0.2). Increasing availability of blood-borne oxidative substrates capable of metabolically bypassing the defect at phosphofructokinase (by fasting plus prolonged moderate exercise to increase plasma free fatty acids or by iv lactate infusion) increased peak work rate, V̇O2, and arteriovenous O2 difference, lacked consistent effect on peak Q̇, and normalized ΔQ̇/ΔV̇O2 in PFKD patients. The results extend our previous observations in patients with a block in muscle glycogen but not blood glucose oxidation due to phosphorylase deficiency and imply that specific unavailability of muscle glycogen as an oxidizable fuel is primarily responsible for abnormal muscle oxidative metabolism and associated exercise intolerance and exaggerated ΔQ̇/ΔV̇O2 in muscle PFKD. The findings also endorse the concept that factors closely linked with muscle oxidative phosphorylation participate in regulating ΔQ̇/ΔV̇O2, likely via activation of metabolically sensitive muscle afferents.

UR - http://www.scopus.com/inward/record.url?scp=0026032744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026032744&partnerID=8YFLogxK

M3 - Article

C2 - 1826293

AN - SCOPUS:0026032744

VL - 70

SP - 391

EP - 398

JO - Journal of Applied Physiology

JF - Journal of Applied Physiology

SN - 0161-7567

IS - 1

ER -